Duality Biotherapeutics (9606) H2 2024 earnings summary

Executive summary

• Leading global developer of antibody-drug conjugates (ADC) for oncology and autoimmune diseases, with 12 proprietary ADC candidates, including 7 in clinical stages and 5 in preclinical stages.

• Core assets DB-1303 (HER2 ADC) and DB-1311 (B7-H3 ADC) are in late-stage clinical development, with multiple global and China-based pivotal trials ongoing.

• Strategic partnerships with BioNTech, BeiGene, Adcendo, GSK, and Avenzo, with total deal value exceeding $6 billion and $500 million received to date.

• No commercial product sales yet; revenue is primarily from out-licensing, milestone payments, and R&D reimbursements.

Financial highlights

• Revenue: RMB 1,941.3 million in 2024, up from RMB 1,786.5 million in 2023, mainly from licensing and collaboration agreements.

• Net loss: RMB 1,050.4 million in 2024, compared to RMB 357.5 million in 2023, driven by increased R&D and administrative expenses.

• R&D expenses: RMB 836.7 million in 2024 (49.7% YoY increase), representing 84.1% of total operating expenses.

• Cash and equivalents: RMB 1,208.9 million as of Dec 31, 2024; total liquidity (including term deposits and restricted cash) RMB 1,435.8 million.

• Gross margin: 40.4% in 2024, down from 76.1% in 2023, due to a shift in revenue mix.

• Main customer: BioNTech accounted for 80.7% of 2024 revenue.

Outlook and guidance

• Plans to continue advancing late-stage clinical assets toward regulatory submissions and commercialization, with DB-1303 expected to file for accelerated approval in 2025.

• Proceeds from the global offering (estimated net HK$1,370.3 million at midpoint) will be allocated primarily to clinical development and commercialization of core and key products, platform innovation, and general corporate purposes.

• Anticipates continued net losses in the near term due to ongoing R&D and pre-commercialization investments.